Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Dipotassium Hydrogen Citrate→

Dipotassium Hydrogen Citrate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
3609-96-9
Molecular formula
C6H6K2O7
Molecular weight
268.3 g/mol
Drug class
Alkalinising agenturinary citrate source and calcium-complexing ligand
Mechanism of action
Citrate is metabolised to bicarbonate, increasing systemic and urinary alkalinity. In urine it complexes calcium and increases urinary citrate, reducing supersaturation of calcium salts and inhibiting stone crystallisation. Sodium or potassium counter-ions affect electrolyte load and patient selection, but do not create a different citrate pharmacological target.
Indications / reported uses
  • Prevention and treatment of recurrent calcium-containing kidney stones associated with hypocitraturia
  • Alkali replacement in selected patients with renal tubular acidosis and hypocitraturia
  • Urinary alkalinisation in selected uric-acid or cystine stone disorders, depending on the specific citrate formulation and local product information

Sources: US DailyMed — Potassium citrate extended-release tablets · NIDDK — Kidney stones prevention and treatment · EAU Guidelines — Urolithiasis

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Alkalinising agent; urinary citrate source and calcium-complexing ligand

Mechanism of action

Citrate is metabolised to bicarbonate, increasing systemic and urinary alkalinity. In urine it complexes calcium and increases urinary citrate, reducing supersaturation of calcium salts and inhibiting stone crystallisation. Sodium or potassium counter-ions affect electrolyte load and patient selection, but do not create a different citrate pharmacological target.

General use cases

  • Prevention and treatment of recurrent calcium-containing kidney stones associated with hypocitraturia
  • Alkali replacement in selected patients with renal tubular acidosis and hypocitraturia
  • Urinary alkalinisation in selected uric-acid or cystine stone disorders, depending on the specific citrate formulation and local product information
Active moiety: citrate (Simple salt/counter-ion form; shares the same API pharmacology and general use cases.)

Citrate provides the alkalinising/complexing moiety. Potassium is a pharmacologically relevant electrolyte and changes safety considerations (e.g. hyperkalaemia), not the core citrate target.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Dipotassium Hydrogen Citrate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Dipotassium Hydrogen Citrate Permitted Daily Exposure (PDE) report (the Dipotassium Hydrogen Citrate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Dipotassium Hydrogen Citrate Occupational Exposure Limit (OEL) report (the Dipotassium Hydrogen Citrate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.